Evaluation of precorneal residence time of brimonidine tartrate nanoparticles loaded in situ gel using gamma scintigraphy

References

• Kowing, D.; Messer, D.; Slagle, S.; Wasik, A. Programs to Optimize Adherence in Glaucoma. Opt. J. Amer. Optomet. Assoc. 2010, 81, 339–350. DOI: 10.1016/j.optm.2009.09.021.
   PubMedGoogle Scholar
• Bucolo, C.; Drago, F. Carbon Monoxide and the Eye: Implications for Glaucoma Therapy. Pharmacol. Ther. 2011, 130, 191–201. DOI: 10.1016/j.pharmthera.2011.01.013.
   PubMed Web of Science ®Google Scholar
• Chen, J.; Runyan, S.; Robinson, M. Novel Ocular Antihypertensive Compounds in Clinical Trials. Clin. Ophthalmol. 2011, 5, 667–677. DOI: 10.2147/OPTH.S15971.
   PubMedGoogle Scholar
• Blomdahl, S.; Calissendorff, B. M.; Tengroth, B.; Wallin, Ö. Blindness in Glaucoma Patients. Acta Ophthalmol. 2009, 75, 589–591. DOI: 10.1111/j.1600-0420.1997.tb00155.x.
   Google Scholar
• Agarwal, R.; Gupta, S.; Agarwal, P.; Saxena, R.; Agrawal, S. S. Current Concepts in the Pathophysiology of Glaucoma. Indian J. Ophthalmol. 2009, 57, 257–566. DOI: 10.4103/0301-4738.53049.
   PubMed Web of Science ®Google Scholar
• Kaur, I. P.; Smitha, R.; Aggarwal, D.; Kapil, M. Acetazolamide: future Perspective in Topical Glaucoma Therapeutics. Int. J. Pharm. 2002, 248, 1–14. DOI: 10.1016/S0378-5173(02)00438-6.
   PubMed Web of Science ®Google Scholar
• Hoyng, P. F.; Van Beek, L. M. Pharmacological Therapy for Glaucoma: A Review. Drugs 2000, 59, 411–434. DOI: 10.2165/00003495-200059030-00003.
   PubMed Web of Science ®Google Scholar
• Oh, D. J.; Chen, J. L.; Vajaranant, T. S.; Dikopf, M. S. Brimonidine tartrate for the treatment of glaucoma. Expert Opin. Pharmacother. 2019, 20, 115–122. DOI: 10.1080/14656566.2018.1544241.
   PubMed Web of Science ®Google Scholar
• Fudemberg, S. J.; Batiste, C.; Katz, L. J. Efficacy, Safety, and Current Applications of Brimonidine. Expert Opin. Drug Saf. 2008, 7, 795–799. DOI: 10.1517/17425250802457609.
   PubMed Web of Science ®Google Scholar
• Schuman, J. S.; Horwitz, B.; Choplin, N. T.; David, R.; Albracht, D.; Chen, K. A 1-Year Study of Brimonidine Twice Daily in Glaucoma and Ocular Hypertension. Arch. Ophthalmol. 1997, 115, 847–852. DOI: 10.1001/archopht.1997.01100160017002.
   PubMed Web of Science ®Google Scholar
• Pal Kaur, I.; Kanwar, M. Ocular Preparations: The Formulation Approach. Drug Dev. Ind. Pharm. 2002, 28, 473–493. DOI: 10.1081/DDC-120003445.
   PubMed Web of Science ®Google Scholar
• Addo RT, editor. Ocular Drug Delivery: Advances, Challenges and Applications. Springer International Publishing; . (Springer Nature Switzerland AG) DOI 10.1007/978-3-319-47691-9
   Google Scholar
• Hornof, M.; Toropainen, E.; Urtti, A. Cell Culture Models of the Ocular Barriers. Eur. J. Pharm. Biopharm. 2005, 60, 207–225. DOI: 10.1016/j.ejpb.2005.01.009.
   PubMed Web of Science ®Google Scholar
• Kumar, S.; Karki, R.; Meena, M.; Prakash, T.; Rajeswari, T.; Goli, D. Reduction in Drop Size of Ophthalmic Topical Drop Preparations and the Impact of Treatment. J. Adv. Pharm. Technol. Res. 2011, 2, 192–195. DOI: 10.4103/2231-4040.85540.
   PubMedGoogle Scholar
• Swarbrick, J.; Boylan, J. Ocular Drug Formulation and Delivery. Encyclopedia of Pharmaceutical Technology. Marcel Dekker, New York 1995; 43–75.
   Google Scholar
• Ranade V. V., Hollinger M. A. Intranasal and Ocular Drug Delivery. Drug Del Sys. CRC press, Boca Raton, FL.1996; 209–238..
   Google Scholar
• Felt, O.; Baeyens, V. Mucosal Drug Delivery: Ocular. Encyclopedia of Controlled Drug Delivery. Encycl. Cont. Drug Del. , Vol II. John Wiley and Sons, 1999, 605–626.
   Google Scholar
• Chiou, G. C. Y; Watanabe, K. Drug Delivery to the Eyes. Methods of Drug Delivery. Int. Encycl. Pharm Ther. G. M. Ihler. Pergamon Press, UK, 1986, 203–210. Section 120
   Google Scholar
• Gupta, H.; Jain, S.; Mathur, R.; Mishra, P.; Mishra, A. K.; Velpandian, T. Sustained Ocular Drug Delivery from a Temperature and pH Triggered Novel in Situ Gel System. Drug Del. 2007, 14, 507–515. DOI: 10.1080/10717540701606426.
   PubMed Web of Science ®Google Scholar
• Akhter, S.; Ramazani, F.; Ahmad, M. Z.; Ahmad, F. J.; Rahman, Z.; Bhatnagar, A. Ocular Pharmacoscintigraphic and Aqueous Humoral Drug Availability of Ganciclovir-Loaded Mucoadhesive Nanoparticles in Rabbits. Eur. J. Nanomed. 2013, 5, 159–167.
   Google Scholar
• Gupta, H.; Aqil, M.; Khar, R. K.; Ali, A.; Bhatnagar, A.; Mittal, G. Sparfloxacin-Loaded PLGA Nanoparticles for Sustained Ocular Drug Delivery. Nanomedicine 2010, 6, 324–333. DOI: 10.1016/j.nano.2009.10.004.
   PubMed Web of Science ®Google Scholar
• Sharma, P. K.; Chauhan, M. K. Optimization and Evaluation of Encapsulated Brimonidine Tartrate-loaded Nanoparticles Incorporation in Situ Gel for Efficient Intraocular Pressure Reduction. J. Sol-Gel Sci. Tech. 2020, 1, 1–12.
   Google Scholar
• Fessi, H.; Puisieux, F.; Devissaguet, J. P.; Ammoury, N.; Benita, S. Nanocapsule Formation by Interfacial Polymer Deposition following Solvent Displacement. Int. J. Pharm. 1989, 55, R1–R4. DOI: 10.1016/0378-5173(89)90281-0.
   Web of Science ®Google Scholar
• Singh, A. K.; Bhardwaj, N.; Bhatnagar, A. Pharmacoscintigraphy: An Unexplored Modality in India. Ind. J. Pharm. Sci. 2004, 66, 18–25.
   Google Scholar
• Okur, N. Ü.; Yozgatlı, V.; Okur, M. E.; Yoltaş, A.; Siafaka, P. I. Improving Therapeutic Efficacy of Voriconazole against Fungal Keratitis: Thermo-Sensitive in Situ Gels as Ophthalmic Drug Carriers. J. Drug Deliv. Sci. Tech. 2019, 49, 323–333. DOI: 10.1016/j.jddst.2018.12.005.
   Web of Science ®Google Scholar
• Okur, N. Ü.; Yozgatli, V.; Okur, M. E. In Vitro-in Vivo Evaluation of Tetrahydrozoline-Loaded Ocular in Situ Gels on Rabbits for Allergic Conjunctivitis Management . Drug Dev. Res. 2020; doi:10.1002/ddr.21677.
   PubMedGoogle Scholar
• Gupta, H.; Aqil, M.; Khar, R. K.; Ali, A.; Bhatnagar, A.; Mittal, G.; Jain, S. Development and Characterization of 99mTc-Timolol Maleate for Evaluating Efficacy of in Situ Ocular Drug Delivery System. AAPS Pharm. Sci. Tech. 2009, 10, 540–546. DOI: 10.1208/s12249-009-9238-x.
   PubMed Web of Science ®Google Scholar
• Raj, P. M.; Raj, R.; Kaul, A.; Mishra, A. K.; Ram, A. Biodistribution and Targeting Potential Assessment of Mucoadhesive Chitosan Nanoparticles Designed for Ulcerative Colitis via Scintigraphy. RSC Adv. 2018, 8, 20809–20821. DOI: 10.1039/C8RA01898G.
   PubMed Web of Science ®Google Scholar
• Oyedele, A. O.; John, O. O.; Ogungbemi, H. O.; Olateju, S. O. Ocular Tolerance and In-vitro Release of Chloramphenicol in Prospective Eye Ointment Bases. Int. J. Pharm. Pharm. Sci. 2015, 7, 306–311.
   Google Scholar
• Jafarieh, O.; Md, S.; Ali, M.; Baboota, S.; Sahni, J. K.; Kumari, B.; Bhatnagar, A.; Ali, J. Design, Characterization, and Evaluation of Intranasal Delivery of Ropinirole-Loaded Mucoadhesive Nanoparticles for Brain Targeting. Drug Dev. Ind. Pharm. 2015, 41, 1674–1681. DOI: 10.3109/03639045.2014.991400.
   PubMed Web of Science ®Google Scholar
• Sharma, B. G.; Kumar, N.; Nishad, D. K.; Khare, N. K.; Bhatnagar, A. Development of Microbial Trigger Based Oral Formulation of Tinidazole and Its Gamma Scintigraphy Evaluation: A Promising Tool against Anaerobic Microbes Associated GI Problems. Eur. J. Pharm. Sci. 2016, 89, 94–104. DOI: 10.1016/j.ejps.2016.04.022.
   PubMed Web of Science ®Google Scholar
• Bhagav, P.; Upadhyay, H.; Chandran, S. Brimonidine Tartrate–Eudragit Long-Acting Nanoparticles: Formulation, Optimization, in Vitro and in Vivo Evaluation. AAPS Pharmscitech. 2011, 12, 1087–1101. DOI: 10.1208/s12249-011-9675-1.
   PubMed Web of Science ®Google Scholar
• Janagam, D. R.; Wu, L.; Lowe, T. L. Nanoparticles for Drug Delivery to the Anterior Segment of the Eye. Adv. Drug Deliv. Rev. 2017, 122, 31–64. DOI: 10.1016/j.addr.2017.04.001.
   PubMed Web of Science ®Google Scholar
• Davis, S. S.; Hardy, J. G.; Newman, S. P.; Wilding, I. R. Gamma Scintigraphy in the Evaluation of Pharmaceutical Dosage Forms. Eur. J. Nucl. Med. 1992, 19, 971–986. DOI: 10.1007/BF00175865..
   PubMedGoogle Scholar